IGF1R and colorectal cancer: The IGF1R mAbs will not prevent signalling via IGF2 binding to the INSR‐A receptor, which would be another route to evade IGF1R inhibition; indeed, increased phospho‐INSR levels have been observed in response to an EGFR inhibitor in colorectal cancer cells (Jones et al., 2006).